Better Therapeutics Overview
Latest ROE for Better Therapeutics: 317.73% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow317.73%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Better Therapeutics (BTTX) currently reports a ROE of 317.73%. That is above the sector sector average of -6.13%. Use the charts on this page to explore Better Therapeutics's ROE history and peer comparisons.
Better Therapeutics's ROE of 317.73% is higher than the its sector sector average of -6.13%. That is roughly 5284.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Better Therapeutics's current 317.73% should be judged against industry norms (sector average: -6.13%) and against BTTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 317.73%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -6.13%. From there, open related valuation or income-statement pages for Better Therapeutics, and consider following BTTX for alerts when major investors trade the stock.
